Stifel Nicolaus Issues Pessimistic Forecast for X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective lowered by stock analysts at Stifel Nicolaus from $30.00 to $9.00 in a research report issued to clients and investors on Friday, MarketBeat reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 139.36% from the company’s previous close.

Separately, HC Wainwright set a $3.50 target price on X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 13th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, X4 Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $34.17.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $3.76 on Friday. The company has a quick ratio of 3.05, a current ratio of 3.19 and a debt-to-equity ratio of 19.10. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $26.83. The stock’s 50 day moving average is $2.19 and its 200-day moving average is $5.12. The firm has a market capitalization of $42.90 million, a price-to-earnings ratio of -0.25 and a beta of 0.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Friday, August 8th. The company reported ($3.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $1.06. X4 Pharmaceuticals had a negative return on equity of 375.31% and a negative net margin of 311.15%.The company had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.62 million. Sell-side analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kingdon Capital Management L.L.C. raised its position in X4 Pharmaceuticals by 41.8% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock valued at $1,655,000 after buying an additional 2,063,000 shares during the last quarter. Pale Fire Capital SE increased its position in shares of X4 Pharmaceuticals by 45.2% during the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock valued at $481,000 after purchasing an additional 633,398 shares during the last quarter. Bank of America Corp DE increased its position in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the last quarter. Rhumbline Advisers increased its position in shares of X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of X4 Pharmaceuticals by 9.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock valued at $114,000 after purchasing an additional 43,320 shares during the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.